These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9022900)

  • 1. Fibrates and HDL cholesterol.
    Murphy MJ; Packard CJ; O'Reilly DS
    Ann Clin Biochem; 1997 Jan; 34 ( Pt 1)():114. PubMed ID: 9022900
    [No Abstract]   [Full Text] [Related]  

  • 2. Fibrate monotherapy and profound hypoalphalipoproteinaemia.
    Olukoga AO; Crowley VE; Stewart MF; Weinkove O
    Postgrad Med J; 1996 Mar; 72(845):189. PubMed ID: 8731722
    [No Abstract]   [Full Text] [Related]  

  • 3. Paradoxical high-density lipoprotein reduction induced by fenofibrate and ciprofibrate.
    Collinson PO; Hjelm CJ; Canepo-Anson R
    Ann Clin Biochem; 1996 Mar; 33 ( Pt 2)():159-61. PubMed ID: 8729728
    [No Abstract]   [Full Text] [Related]  

  • 4. Transitory deficit in high-density lipoproteins and apolipoprotein A-I.
    Legras B; Clerc C; Ruelland A; Doualin G; Fertil V; Cloarec L
    Clin Chem; 1990 Mar; 36(3):580-1. PubMed ID: 2107044
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia.
    Okopien B; Cwalina L; Lebek M; Kowalski J; Zielinski M; Wisniewska-Wanat M; Kalina Z; Herman ZS
    Int J Clin Pharmacol Ther; 2001 Dec; 39(12):551-7. PubMed ID: 11770837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid profiles on fibric-acid derivatives.
    Capps NE
    Lancet; 1994 Sep; 344(8923):684-5. PubMed ID: 7915370
    [No Abstract]   [Full Text] [Related]  

  • 7. Implication of fibrate therapy for homocysteine.
    Goffin E; Jamar F; Desager JP; Devuyst O
    Lancet; 1999 Oct; 354(9185):1209. PubMed ID: 10513738
    [No Abstract]   [Full Text] [Related]  

  • 8. Ciprofibrate and lipid profile.
    Chandler HA; Batchelor AJ
    Lancet; 1994 Jul; 344(8915):128-9. PubMed ID: 7912363
    [No Abstract]   [Full Text] [Related]  

  • 9. Abnormal lipid profiles on fibrate derivatives.
    McLeod AJ; Warren RJ; Armitage M
    Lancet; 1996 Jan; 347(8996):261. PubMed ID: 8551900
    [No Abstract]   [Full Text] [Related]  

  • 10. [Antilipemic therapy in dyslipidemias in obese non-insulin-dependent diabetics (ONIDDM)].
    Palel G; Coman A; Petrovanu R; Ungureanu D; Cojocaru M
    Rev Med Chir Soc Med Nat Iasi; 1997; 101(3-4):120-2. PubMed ID: 10756782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of fibrates on lipoprotein and hemostatic coronary risk factors.
    Schonfeld G
    Atherosclerosis; 1994 Dec; 111(2):161-74. PubMed ID: 7718018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential associations of statin and fibrate treatment with carotid arterial remodeling.
    Chironi G; Simon A; Gariepy J; Balice M; Del-Pino M; Levenson J
    Am J Hypertens; 2005 Nov; 18(11):1476-81. PubMed ID: 16280285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of fibric acid derivatives on biliary lipid composition.
    Palmer RH
    Am J Med; 1987 Nov; 83(5B):37-43. PubMed ID: 3318452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CORONARY EFFECT OF FIBRATES ON PROTEINS AND ENZYMES WHICH HYDROLYZE TRIACYLGLYCEROLS.
    Francik R; Kryczyk J; Francik S
    Acta Pol Pharm; 2016; 73(3):579-88. PubMed ID: 27476274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrates and renal function.
    Gajdos M; Dzúrik R
    Clin Nephrol; 2003 Jul; 60(1):65-6. PubMed ID: 12872864
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of initial BMI and on-treatment weight change on the lipid-lowering efficacy of fibrates.
    Muls E; Van Gaal L; Autier P; Vansant G
    Int J Obes Relat Metab Disord; 1997 Feb; 21(2):155-8. PubMed ID: 9043971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1500 mg.
    Wi J; Kim JY; Park S; Kang SM; Jang Y; Chung N; Shim WH; Cho SY; Lee SH
    Atherosclerosis; 2010 Nov; 213(1):235-40. PubMed ID: 20855072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ciprofibrate and lipid profile.
    McLeod AJ; Warren RJ; Armitage M
    Lancet; 1994 Oct; 344(8927):955. PubMed ID: 7934365
    [No Abstract]   [Full Text] [Related]  

  • 19. Iatrogenic profound hypoalphalipoproteinaemia: an unrecognised cause of very low HDL cholesterol.
    Murphy MJ; Duncan A; Vallance BD; Packard CJ; O'Reilly DS
    Postgrad Med J; 1995 Aug; 71(838):498-500. PubMed ID: 7567762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cytolytic hepatic damage caused by ciprofibrate].
    Perault MC; Fievre JL; Dejean C; Martin A; Vandel B
    Gastroenterol Clin Biol; 1992; 16(6-7):609. PubMed ID: 1526424
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.